...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
【24h】

The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.

机译：通过定量唾液腺闪烁显像法测量，氨磷汀或IMRT保留头颈部区域放疗后保留腮腺功能的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: In this retrospective study, two approaches to preserve the parotid function after radiotherapy (RT) were compared: application of the radioprotective agent amifostine during RT and parotid-sparing intensity-modulated radiotherapy (IMRT). PATIENTS AND METHODS: Patients were qualified for this analysis if (1) both parotid glands received a radiation dose of 50Gy using conventional radiotherapy techniques (cRT) or if they received a parotid-sparing IMRT as alternative, if (2) salivary gland scintigraphies before and after RT were performed, and if (3) a normal parotid function was present before RT. Quantitative salivary gland scintigraphy was used to assess the parotid gland function. RESULTS: Altogether 275 salivary gland scintigraphies of 100 patients were analyzed. The mean relative tracer uptake (DeltaU) of patients treated with cRT, cRT with amifostine and IMRT 1-12 months after RT was 0.59 (95%CI 0.54-0.65), 0.67 (95%CI 0.59-0.76), and 0.93 (95%CI 0.78-1.07), respectively. The mean relative DeltaU 13-47 months after RT was 0.40 (95%CI 0.32-0.49), 0.60 (95%CI 0.48-0.71), and 0.92 (95%CI 0.56-1.28). At 1-12 months after RT, ANOVA testing with post-hoc comparison using the Bonferroni correction showed a significant difference between IMRT and cRT (p<0.001) or IMRT and amifostine (p<0.01). The difference between amifostine and cRT was not significant during the first year. At 13-47 months after RT, the difference between cRT and amifostine was significant (p=0.02). CONCLUSION: Our data suggest that both amifostine and IMRT are able to partially preserve the parotid function after radiotherapy. The effect of IMRT appeared to be much greater.
机译：目的：在这项回顾性研究中，比较了两种在放疗（RT）后保留腮腺功能的方法：放疗期间应用放射防护剂氨磷汀和保留腮腺的调强放疗（IMRT）。患者和方法：如果（1）两个腮腺均接受了常规放射疗法（cRT）的50Gy放射剂量，或者如果他们接受了保留腮腺的IMRT作为替代物，则患者（2）之前唾液腺闪烁显像并且在进行RT后，如果（3）在RT前存在正常的腮腺功能。定量唾液腺闪烁显像术用于评估腮腺功能。结果：共分析了100例患者的275例唾液腺闪烁显像。 RT后1-12个月接受cRT，cRT联合氨磷汀和IMRT治疗的患者的平均相对示踪剂摄取量（DeltaU）为0.59（95％CI 0.54-0.65），0.67（95％CI 0.59-0.76）和0.93（95） ％CI 0.78-1.07）。放疗后13-47个月的平均相对DeltaU为0.40（95％CI 0.32-0.49），0.60（95％CI 0.48-0.71）和0.92（95％CI 0.56-1.28）。在放疗后1-12个月，采用Bonferroni校正进行事后比较的ANOVA测试显示IMRT和cRT（p <0.001）或IMRT和氨磷汀（p <0.01）之间存在显着差异。在第一年，氨磷汀和cRT之间的差异并不显着。放疗后13-47个月，cRT和氨磷汀之间的差异显着（p = 0.02）。结论：我们的数据表明，氨磷汀和IMRT都能在放射治疗后部分保留腮腺功能。 IMRT的效果似乎要大得多。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号